Insights into the redox cycle of human quinone reductase 2

References

• Venugopal R, Joseph P, Jaiswal AK. Gene expression of DT-diaphorase in cancer cells. Henry JF, Enrique C. Oxidative stress and signal transduction. New York: Chapman & Hall; 1997. 441–475.
   Google Scholar
• Talalay P, Fahey JW, Holtzclaw WD, Prestera T, Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett 1995;82–83:173–179.
   Google Scholar
• Riley RJ, Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharm 1992;43:1657–1669.
   PubMed Web of Science ®Google Scholar
• Long DJ II, Jaiswal AK. Mouse NRH:quinone oxidoreductase (NQO2): cloning of cDNA and gene- and tissue-specific expression. Gene 2000;252:107–117.
   PubMed Web of Science ®Google Scholar
• Kappus H, Sies H. Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation. Experientia 1981;37:1233–1241.
   PubMedGoogle Scholar
• Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000; 13:135–160.
   PubMed Web of Science ®Google Scholar
• Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D, NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 2000;129:77–97.
   PubMed Web of Science ®Google Scholar
• Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res 2010;70(3):1006–1014.
   Google Scholar
• Ross D, Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115–144.
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Izawa T, Usami M, Ohnuma T, Ogura K, Hiratsuka A. UDP-glucuronosyltransferases 1A6 and 1A10 catalyze reduced menadione glucuronidation. Biochem Biophys Res Commun 2010;394:459–463.
   PubMed Web of Science ®Google Scholar
• Chen S, Wu KB, Knox R. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med 2000;29:276–284.
   PubMed Web of Science ®Google Scholar
• Li R, Bianchet MA, Talalay P, Amzel LM. The three- dimensional structure of NAD(P)H: quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci U S A. 1995;92:8846–8850.
   PubMed Web of Science ®Google Scholar
• Foster CE, Bianchet MA, Talalay P, Zhao Q, Amzel LM. Crystal structure of human quinone reductase. Biochemistry 1999;38:9881–9886.
   PubMed Web of Science ®Google Scholar
• Wu K, Knox R, Sun XZ, Joseph P, Jaiswal AK, Zhang D, . Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997;347:221, 8.
   PubMed Web of Science ®Google Scholar
• Long DJ II, Iskander K, Gaikwad A, Arin M, Roop D, Knox R, . Disruption of NRH:quinone oxidoreductase2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277:46131–46139.
   PubMed Web of Science ®Google Scholar
• Vella F, Ferry G, Delagrange P, Boutin JA. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005;71:1–12.
   PubMed Web of Science ®Google Scholar
• Calamini B, Santarsiero BD, Boutin JA, Mesecar AD. Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2. Biochem J 2008;413:81–91.
   PubMed Web of Science ®Google Scholar
• Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004;43:11417–11426.
   PubMed Web of Science ®Google Scholar
• Ferry G, Hecht S, Berger S, Moulharat N, Coge F, Guillaumet G, . Old and new inhibitors of quinone reductase 2. Chem Biol Interact 2010 Jul 30;186:103–109.
   Google Scholar
• Mailliet F, Ferry G, Vella F, Berger S, Cog F, Chomarat P, . Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005;71:74–88.
   Google Scholar
• Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, . Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000;275: 31311–31317.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Chatelain-Egger F, Vella F, Delagrange P, Ferry G. Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem Biol Interact 2005;151:213–228.
   PubMed Web of Science ®Google Scholar
• Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, . Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med 2010;2:40–50.
   Web of Science ®Google Scholar
• Christofferson A, Wilkie J. Mechanism of CB1954 reduction by Escherichia coli nitroreductase. Biochem Soc Trans 2009; 37:413–418.
   Google Scholar
• Qiu XB, Cadenas E. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells. Arch Biochem Biophys 1997;346: 241–251.
   PubMed Web of Science ®Google Scholar
• Nutter LM, Ngo E, Fisher GR, Gutierrez PL. DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. J Biol Chem 1992;267: 2474–2479.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Yang XL, Holtzclaw WD, Talalay P. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase). Proc Natl Acad Sci U S A 1997;94:1669–1674.
   PubMed Web of Science ®Google Scholar
• Jaiswal AK. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991;30:10647–10653.
   PubMed Web of Science ®Google Scholar
• Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004;43(15):4538–4547.
   Google Scholar
• Zhu BZ, Kalyanaraman B, Jiang GB. Molecular mechanism for metal-independent production of hydroxyl radicals by hydrogen peroxide and halogenated quinones. Proc Natl Acad Sci U S A 2007;104(45):17575–17578.
   Google Scholar
• Hasinoff BB, Begleiter A. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells. Free Radic Res 2006;40(9):974–978.
   Google Scholar
• Cadenas E. Antioxidant and prooxydant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995;49:127–140.
   PubMed Web of Science ®Google Scholar
• Fridovich I. The biology of oxygen radicals. Science 1978; 201:875–880.
   PubMed Web of Science ®Google Scholar
• Pedersen JA. On the application of electron paramagnetic resonance in the study of naturally occurring quinones and quinols. Spectrochim Acta A Mol Biomol Spectrosc 2002; 58:1257–1270.
   PubMed Web of Science ®Google Scholar
• Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 2004;36:639–654.
   PubMed Web of Science ®Google Scholar
• Audi SH, Zhao H, Bongard RD, Hogg N, Kettenhofen NJ, Kalyanaraman B, . Pulmonary arterial endothelial cells affect the redox status of coenzyme Q0. Free Rad Biol Med 2003;34:892–907.
   Google Scholar
• Linnane AW, Kios M, Vitetta L. Coenzyme Q(10)-its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion 2007;7 Suppl:S51–S56
   Google Scholar
• King MS, Sharpley MS, Hirst J. Reduction of hydrophilic ubiquinones by the flavin in tmitochondria NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species. Biochemistry 2009;48:2053–2062.
   Google Scholar
• Celli CM, Tran N, Knox R, Jaiswal AK. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006; 72:366–376.
   Google Scholar
• Jaiswal AK, Bell DW, Radjendirane V, Testa JR. Localization of human NQO1 gene to chromosome 16q22 and NQO2-6p25 and associated polymorphisms. Pharmacogenetics 1999;9: 413–418.
   PubMedGoogle Scholar
• Hosoda S, Nakamura W, Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver. J Biol Chem 1974; 249:6416–6423.
   PubMed Web of Science ®Google Scholar
• Maiti A, Reddy PV, Sturdy M, Marler L, Pegan SD, Mesecar AD, . Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem 2009;52:1873–1884.
   Google Scholar
• Boutin, JA. Indirect evidences of UDP-glucuronosyltransferase heterogeneity: how can it help purification? Drug Metab Rev 1987;18:517–551.
   PubMed Web of Science ®Google Scholar
• Ma Q, Lu AY. The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters. Curr Drug Metab 2008;9:374–383.
   Google Scholar
• Benoit CE, Bastianetto S, Brouillette J, Tse YC, Boutin JA, Delagrange P, . Loss of quinone reductase 2 function selectively facilitates learning behaviours. J Neurosci 2010; 30:12690–12700.
   PubMed Web of Science ®Google Scholar
• Wang W, Jaiswal AK. Sp3 repression of polymorphic human NRH:quinone oxidoreductase 2 gene promoter. Free Radic Biol Med 2004;37:1231–1243.
   PubMedGoogle Scholar